Date: 2017-01-25
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Abbvie (USA - IL)
Product: ABBV-8E12/C2N-8E12
Action
mechanism: monoclonal antibody. ABBV-8E12/C2N-8E12 is a humanized antibody targeting the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as progressive supranuclear palsy and Alzheimer's disease. On March 19, 2015, AbbVie and C2N Diagnostics have entered into an exclusive worldwide license agreement to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders.
Disease: Alzheimer's Disease
Therapeutic area: Neurodegenerative diseases
Country: Australia, New Zealand, USA
Trial
details: This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease. (NCT02880956)
Latest
news: * On January 25, 2017, AbbVie announced the start of a Phase 2 clinical trial program to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with early Alzheimer's disease. The Phase 2 study in early Alzheimer's disease will enroll 400 patients to assess the efficacy and safety of ABBV-8E12 to delay disease progression.
